Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 597-malignant-breast-disorders-with-mcc
    Ask Trek AI about this page

    Malignant Breast Disorders with MCC: Inpatient Reimbursement Overview

    DRG 597 addresses hospital stays for malignant breast disorders complicated by a Major Complication or Comorbidity, encompassing advanced disease or significant perioperative or treatment-related complications. It matters for inpatient reimbursement because assignment to this Diagnosis-Related Group reflects higher resource needs and results in increased Medicare payment relative to less complex groupings.

    Customize your policy alerts

    Sign up for drg 597 policy alerts

    Get alerted when payer policies referencing 597 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 597 Overview

    DRG 597 covers inpatient admissions for malignant breast disorders when a Major Complication or Comorbidity is present, typically involving advanced tumor burden, invasive procedures with significant perioperative issues, or serious treatment-related infections or complications. This Diagnosis-Related Group groups patients who require higher resource use and intensified inpatient management, which influences payment under Medicare inpatient prospective payment systems. Accurate clinical documentation and coding of the underlying malignancy and the Major Complication or Comorbidity affect the assignment to DRG 597 and corresponding reimbursement. The classification is important for hospitals because it aligns payment with the increased intensity of care and resource consumption associated with complex malignant breast disease.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative and neoadjuvant therapy trials assessing optimal sequencing and intensity of systemic therapy for patients with locally advanced or high-risk malignant breast disorders who present with major comorbidities or complications. These studies enroll patients requiring inpatient management for complications (such as infection, bleeding, or tumor-related obstruction) or those with significant medical complexity that may alter tolerance to standard chemotherapy or targeted agents; investigators evaluate response rates, feasibility of delivering neoadjuvant regimens, and short-term surgical outcomes. Results inform clinicians and payers about which preoperative approaches reduce inpatient length of stay, minimize escalation of care, and improve operability in medically complex patients, helping to align treatment planning with resource use.
    • Comparative effectiveness studies of surgical approaches and perioperative management in patients with malignant breast disorders complicated by major comorbid conditions or postoperative complications. These trials compare outcomes such as complication rates, readmissions, need for reoperation, and functional recovery between different surgical techniques, reconstruction timing strategies, or enhanced recovery protocols specifically in frail or medically complex populations. Findings help providers choose approaches that lower complication-driven hospital utilization and guide payers on which care pathways yield better value and reduced downstream costs for high-risk inpatient cohorts.
    • Post-discharge outcomes and survivorship research focusing on readmission prevention, management of treatment-related toxicities, and coordination of multidisciplinary care for patients initially hospitalized with malignant breast disorders and major complications. These observational and interventional studies target transitions of care, home- and clinic-based monitoring, and symptom-management programs for patients with significant comorbidity burdens to reduce early readmissions and emergency visits. For hospitals and payers, this evidence is critical to designing post-acute services that improve patient outcomes while controlling readmission-related expenditures associated with this DRG.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.